オプションチェーンは、Cloroxの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Cloroxの市場センチメントを評価します。.

Clorox (NYSE:CLX) 株価情報, オプションチェーン

Clorox

Since its inception more than 100 years ago, Clorox has grown to play in a variety of categories across the consumer products space, including cleaning supplies, laundry care, trash bags, cat litter, charcoal, food dressings, water-filtration products, and natural personal-care products. Beyond its namesake brand, the firm's portfolio includes Liquid-Plumr, Pine-Sol, S.O.S, Tilex, Kingsford, Fresh Step, Glad, Hidden Valley, KC Masterpiece, Brita, and Burt's Bees. Just less than 85% of Clorox's sales stem from its home turf.

Clorox Co

Calix Ltd

COLLEXIS HOLDINGS INC by Collexis Holdings, Inc.

Collexis Holdings Inc

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/580f253b846faa000139ba71/robert-moskow">TD Cowen analyst Robert Moskow</a> upgraded the rating for The Clorox Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) from Sell to Hold and raises the price target from $155 to $170. Clorox shares closed at $162.42 on Tuesday. <a href="https://www.benzinga.com/quote/CLX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays analyst Trevor Young upgraded Revolve Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RVLV#NYSE">RVLV</a>) from Underweight to Equal-Weight and raised the price target from $17 to $25. Revolve shares closed at $26.02 on Tuesday. <a href="https://www.benzinga.com/quote/RVLV/analyst-ratings">See how other analysts view this stock</a>.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/616e99feb650db000151570b/rick-bienkowski">Leerink Partners analyst Rick Bienkowski</a> upgraded the rating for Beam Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>) from Market Perform to Outperform and increased the price target from $27 to $39. Beam Therapeutics shares closed at $23.93 on Tuesday. <a href="https://www.benzinga.com/quote/BEAM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Deutsche Bank analyst David Begleiter upgraded Celanese Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) from Hold to Buy and lowered the price target from $135 to $110. Celanese shares closed at $91.00 on Tuesday. <a href="https://www.benzinga.com/quote/CE/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>

Considering buying CLX stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="547" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06082758/image-49-1024x547.png" alt="" class="wp-image-632747" style="width:636px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06082758/image-49-1024x547.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06082758/image-49-300x160.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06082758/image-49-768x410.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06082758/image-49.png 1230w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41744659/jim-cramer-says-he-cant-recommend-this-major-automaker-ceva-is-way-too-high">Jim Cramer Says He Can&#8217;t Recommend This Major Automaker, Ceva Is &#8216;Way Too High&#8217;</a></li>
</ul>

News

Upgrades

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

BEAM

RVLV

This Clorox Analyst Is No Longer Bearish; Here Are Top 4 Upgrades For Wednesday

TD Cowen analyst Robert Moskow upgrades Clorox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) from Sell to Hold and raises the price target from $155 to $170.

Price Target

TD Cowen Upgrades Clorox to Hold, Raises Price Target to $170

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>B. Riley Securities slashed The Estée Lauder Companies Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EL#NYSE">EL</a>) price target from $95 to $70. B. Riley Securities analyst Anna Glaessgen maintained a Neutral rating. Estée Lauder shares closed at $66.58 on Friday. <a href="https://www.benzinga.com/quote/EL/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Morgan Stanley raised the price target for Mastercard Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MA#NYSE">MA</a>) from $540 to $544. Morgan Stanley analyst James Faucette maintained an Overweight rating. Mastercard shares closed at $508.08 on Friday. <a href="https://www.benzinga.com/quote/MA/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Deutsche Bank cut the price target for Wayfair Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/W#NYSE">W</a>) from $69 to $46. Deutsche Bank analyst Lee Horowitz maintained a Buy rating. Wayfair shares closed at $40.15 on Friday. <a href="https://www.benzinga.com/quote/W/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>RBC Capital increased Reinsurance Group of America, Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RGA#NYSE">RGA</a>) price target from $235 to $245. RBC Capital analyst Scott Heleniak maintained an Outperform rating. Reinsurance Group shares settled at $215.10 on Friday. <a href="https://www.benzinga.com/quote/RGA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barrington Research slashed Insight Enterprises, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NSIT#NASDAQ">NSIT</a>) price target from $225 to $205. Barrington Research analyst Vincent Colicchio maintained an Outperform rating. Insight Enterprises shares closed at $172.21 on Friday. <a href="https://www.benzinga.com/quote/NSIT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>DA Davidson raised The Clorox Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) price target from $153 to $171. DA Davidson analyst Linda Bolton Weiser maintained a Neutral rating. Clorox shares closed at $163.11 on Friday. <a href="https://www.benzinga.com/quote/CLX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Craig-Hallum increased the price target for CVRx, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVRX#NASDAQ">CVRX</a>) from $15 to $20. Craig-Hallum analyst Alexander Nowak maintained a Buy rating. CVRx shares settled at $13.40 on Friday. <a href="https://www.benzinga.com/quote/CVRX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wedbush cut Super Micro Computer, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) price target from $62 to $32. Wedbush analyst Matt Bryson maintained a Neutral rating. Super Micro Computer shares closed at $26.05 on Friday. <a href="https://www.benzinga.com/quote/SMCI/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Roth MKM lowered the price target for Energy Fuels Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UUUU#NYSE">UUUU</a>) from $6 to $5.5. Roth MKM analyst Joe Reagor maintained a Neutral rating. Energy Fuels shares closed at $5.60 on Friday. <a href="https://www.benzinga.com/quote/UUUU/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>UBS boosted Broadcom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) price target from $170 to $200. UBS analyst Timothy Arcuri maintained a Buy rating. Broadcom shares closed at $168.92 on Friday. <a href="https://www.benzinga.com/quote/AVGO/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41713185/top-4-tech-and-telecom-stocks-that-may-collapse-this-month">Top 4 Tech And Telecom Stocks That May Collapse This Month</a></li>
</ul>

Intraday Update

AVGO

CVRX

NSIT

SMCI

UUUU

Broadcom To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Monday

DA Davidson analyst Linda Bolton Weiser maintains Clorox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) with a Neutral and raises the price target from $153 to $171.

DA Davidson Maintains Neutral on Clorox, Raises Price Target to $171

Across the recent three months, 9 analysts have shared their insights on Clorox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $154.89, a high estimate of $187.00, and a low estimate of $130.00. This upward trend is apparent, with the current average reflecting a 6.09% increase from the previous average price target of $146.00.
<img src="https://www.benzinga.com/files/images/story/2024/1730487623_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The standing of Clorox among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lauren Lieberman</td>
<td>Barclays</td>
<td>Raises</td>
<td>Underweight</td>
<td>$139.00</td>
<td>$137.00</td>
</tr>
<tr>
<td>Javier Escalante</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$139.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Lauren Lieberman</td>
<td>Barclays</td>
<td>Raises</td>
<td>Underweight</td>
<td>$137.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Andrea Teixeira</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$174.00</td>
<td>$148.00</td>
</tr>
<tr>
<td>Kaumil Gajrawala</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$187.00</td>
<td>$174.00</td>
</tr>
<tr>
<td>Wendy Nicholson</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$170.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Linda Bolton Weiser</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$153.00</td>
<td>$153.00</td>
</tr>
<tr>
<td>Wendy Nicholson</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$165.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Lauren Lieberman</td>
<td>Barclays</td>
<td>Raises</td>
<td>Underweight</td>
<td>$130.00</td>
<td>$122.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Clorox. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Clorox compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Clorox's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Clorox's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/CLX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Clorox analyst ratings.</a>
<h2>Delving into Clorox's Background</h2>
Since its inception more than 100 years ago, Clorox has grown to play in a variety of categories across the consumer products space, including cleaning supplies, laundry care, trash bags, cat litter, charcoal, food dressings, water-filtration products, and natural personal-care products. Beyond its namesake brand, the firm's portfolio includes Liquid-Plumr, Pine-Sol, S.O.S, Tilex, Kingsford, Fresh Step, Glad, Hidden Valley, KC Masterpiece, Brita, and Burt's Bees. Just less than 85% of Clorox's sales stem from its home turf.
<h3>A Deep Dive into Clorox's Financials</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Clorox's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 27.13% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Consumer Staples sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 5.62%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Clorox's ROE excels beyond industry benchmarks, reaching 51.03%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Clorox's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 1.76%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Clorox's debt-to-equity ratio surpasses industry norms, standing at 48.07. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>How Are Analyst Ratings Determined?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Expert Outlook: Clorox Through The Eyes Of 9 Analysts

Barclays analyst Lauren Lieberman maintains Clorox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) with a Underweight and raises the price target from $137 to $139.

Barclays Maintains Underweight on Clorox, Raises Price Target to $139

Clorox Sees FY25 Adj. EPS $6.65-$6.90 (Prior $6.55-$6.80), Sees FY25 Gross Margin Up 100-150 Bps (Prior Up ~100 Bps)

Clorox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) reported quarterly earnings of $1.86 per share which beat the analyst consensus estimate of $1.39 by 33.81 percent. The company reported quarterly sales of $1.762 billion which beat the analyst consensus estimate of $1.646 billion by 7.05 percent. This is a 27.13 percent increase over sales of $1.386 billion the same period last year.

Earnings

Earnings Beats

Clorox Q1 2025 Adj. EPS $1.86 Beats $1.39 Estimate, Sales $1.762B Beat $1.646B Estimate

Looking into the current session, Clorox Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) shares are trading at $159.01, after a 0.86% decrease. Over the past month, the stock fell by 3.39%, but over the past year, it actually increased by 30.37%. With questionable short-term performance like this, and great long-term performance, long-term shareholders might want to start looking into the company's price-to-earnings ratio. 

<img src="https://www.benzinga.com/files/images/story/2024/1729621890_0.png" alt="Past Year Chart" />

<h3>How Does Clorox P/E Compare to Other Companies?</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Clorox has a better P/E ratio of 71.28 than the aggregate P/E ratio of 43.32 of the Household Products industry. Ideally, one might believe that Clorox Inc. might perform better in the future than it's industry group, but it's probable that the stock is overvalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1729621890_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

A Look Into Clorox Inc's Price Over Earnings

Evercore ISI Group analyst Javier Escalante maintains Clorox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) with a Underperform and lowers the price target from $140 to $139.

Evercore ISI Group Maintains Underperform on Clorox, Lowers Price Target to $139

Barclays analyst Lauren Lieberman maintains Clorox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) with a Underweight and raises the price target from $130 to $137.

Barclays Maintains Underweight on Clorox, Raises Price Target to $137

JP Morgan analyst Andrea Teixeira maintains Clorox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) with a Neutral and raises the price target from $148 to $174.

JP Morgan Maintains Neutral on Clorox, Raises Price Target to $174

As the third-quarter earnings season approaches, Goldman Sachs has issued a note identifying key stock opportunities for investors looking to profit <a href="https://www.benzinga.com/news/earnings/24/10/41255250/banks-gear-up-for-earnings-season-15-top-stock-picks-including-citigroup-morgan-stanley-and-truist">from financial results.</a>
Analyst John Marshall and his team shared their insights on Thursday, highlighting 18 stocks that could benefit from upward earnings revisions and seven stocks likely to face downward revisions.
<h3 class="wp-block-heading">The &#8216;Stock Picker&#8217;s Year&#8217;: 10% Upside In S&amp;P 500</h3>
Goldman Sachs analysts call 2024 "the year of the stock picker," emphasizing the importance of selective investing in a volatile earnings environment.
According to the investment bank&#8217;s latest projections, the average S&amp;P 500 stock could see a 10% upside over the next 12 months. 
"We see relief rally potential," Marshall stated in his note. "Directional positioning in the options market is balanced, a much better set-up than this time last quarter."
The analysts also observed that activity in options markets, both from hedge funds and retail traders, has decreased recently, signaling a "wait-and-see" approach as investors prepare for third-quarter earnings reports and the upcoming U.S. elections.
<h3 class="wp-block-heading">Earnings Season Volatility Remains Elevated</h3>
Goldman Sachs highlighted that single-stock volatility surrounding earnings events remains at a 14-year high. 
This trend, driven by critical market debates on topics like artificial intelligence, interest rates, and the upcoming election, is expected to continue through the remainder of the year.
&#8220;We expect earnings day moves to remain elevated as most of the key debates for the market have winners and losers in the equity space,&#8221; the note added. 
With this heightened volatility, the firm continues to recommend options-based strategies, advising investors to consider buying options ahead of earnings events and selling options between earnings periods to capitalize on price movements.
<h3 class="wp-block-heading">18 Stocks Goldman Sachs Is Bullish On For Third-Quarter Earnings</h3>
Goldman Sachs&#8217; analysts have identified 18 stocks they believe are primed for upside as earnings revisions could be favorable. These stocks span a variety of sectors, from energy and financials to healthcare and technology.
<figure class="wp-block-table is-style-stripes"> 
<table>
<thead>
<tr>
<th>Company</th>
<th>Sector</th>
<th>Earnings Date (e)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gap Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GAP#NYSE">GAP</a>)</td>
<td>Discretionary</td>
<td>Nov. 15</td>
</tr>
<tr>
<td>Permian Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PR#NYSE">PR</a>)</td>
<td>Energy</td>
<td>Nov. 7</td>
</tr>
<tr>
<td>Citigroup Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/C#NYSE">C</a>)</td>
<td>Financials</td>
<td>Oct. 15</td>
</tr>
<tr>
<td>Synchrony Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYF#NYSE">SYF</a>)</td>
<td>Financials</td>
<td>Oct. 16</td>
</tr>
<tr>
<td>Amgen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>)</td>
<td>Healthcare</td>
<td>Oct. 30</td>
</tr>
<tr>
<td>Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>)</td>
<td>Healthcare</td>
<td>Oct. 23</td>
</tr>
<tr>
<td>Merck &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>)</td>
<td>Healthcare</td>
<td>Oct. 31</td>
</tr>
<tr>
<td>Qiagen NV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QGEN#NYSE">QGEN</a>)</td>
<td>Healthcare</td>
<td>Oct. 30</td>
</tr>
<tr>
<td>AZEK Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZEK#NYSE">AZEK</a>)</td>
<td>Industrials</td>
<td>Nov. 29</td>
</tr>
<tr>
<td>ADT Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADT#NYSE">ADT</a>)</td>
<td>TMT</td>
<td>Nov. 1</td>
</tr>
<tr>
<td>Broadcom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>)</td>
<td>TMT</td>
<td>Dec. 6</td>
</tr>
<tr>
<td>Dell Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>)</td>
<td>TMT</td>
<td>Nov. 25</td>
</tr>
<tr>
<td>Klaviyo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KVYO#NYSE">KVYO</a>)</td>
<td>TMT</td>
<td>Nov. 7</td>
</tr>
<tr>
<td>Monday.com Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNDY#NASDAQ">MNDY</a>)</td>
<td>TMT</td>
<td>Nov. 13</td>
</tr>
<tr>
<td>Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)</td>
<td>TMT</td>
<td>Nov. 21</td>
</tr>
<tr>
<td>Snowflake Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>)</td>
<td>TMT</td>
<td>Nov. 29</td>
</tr>
<tr>
<td>Toast Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOST#NYSE">TOST</a>)</td>
<td>TMT</td>
<td>Nov. 7</td>
</tr>
<tr>
<td>Sempra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SRE#NYSE">SRE</a>)</td>
<td>Utilities</td>
<td>Nov. 4</td>
</tr>
</tbody>
</table>
</figure>
<h3 class="wp-block-heading">7 Stocks Goldman Sachs Is Bearish On For Third-Quarter Earnings</h3>
In contrast, the investment bank has identified seven stocks that they expect to face downward earnings revisions in the third quarter, advising investors to exercise caution.
<figure class="wp-block-table is-style-stripes"> 
<table>
<thead>
<tr>
<th>Company</th>
<th>Sector</th>
<th>Earnings Date (e)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Choice Hotels (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHH#NYSE">CHH</a>)</td>
<td>Discretionary</td>
<td>Nov. 7</td>
</tr>
<tr>
<td>Cheniere Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CQP#NYSE">CQP</a>)</td>
<td>Energy</td>
<td>Nov. 1</td>
</tr>
<tr>
<td>Janus Henderson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JHG#NYSE">JHG</a>)</td>
<td>Financials</td>
<td>Oct. 31</td>
</tr>
<tr>
<td>LyondellBasell (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYB#NYSE">LYB</a>)</td>
<td>Materials</td>
<td>Nov. 1</td>
</tr>
<tr>
<td>Clorox Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>)</td>
<td>Staples</td>
<td>Nov. 1</td>
</tr>
<tr>
<td>Kraft Heinz Co. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KHC#NASDAQ">KHC</a>)</td>
<td>Staples</td>
<td>Oct. 30</td>
</tr>
<tr>
<td>Upstart Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPST#NASDAQ">UPST</a>)</td>
<td>TMT</td>
<td>Nov. 7</td>
</tr>
</tbody>
</table>
</figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41278012/feds-goolsbee-downplays-inflation-uptick-economists-hold-steady-on-november-rate-in">Fed&#8217;s Goolsbee Downplays Inflation Uptick, Economists Hold Steady On November Rate Interest Rate Cut Call</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Analyst Color

Equities

Large Cap

Mid Cap

Tech

ETFs

AMGN

AZEK

DELL

Janus Henderson Group plc Ordinary Shares

KVYO

MNDY

NVDA

QGEN

SNOW

TOST

UPST

18 Stocks To Buy, 7 To Sell This Earnings Season: Goldman Sachs Calls It 'The Year Of The Stock Picker'

Linda Rendle, Chief Executive Officer at Clorox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>), disclosed an insider purchase on October 8, based on a new SEC filing.
What Happened: In a significant move reported in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000021076/000122520824009227//Archives/edgar/data/21076/000122520824009227/0001225208-24-009227-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday, Rendle purchased 32,639 shares of Clorox, demonstrating confidence in the company's growth potential. The total value of the transaction stands at $5,273,483.
Tracking the Wednesday's morning session, Clorox shares are trading at $158.89, showing a down of 0.56%.
<h3>About Clorox</h3>
Since its inception more than 100 years ago, Clorox has grown to play in a variety of categories across the consumer products space, including cleaning supplies, laundry care, trash bags, cat litter, charcoal, food dressings, water-filtration products, and natural personal-care products. Beyond its namesake brand, the firm's portfolio includes Liquid-Plumr, Pine-Sol, S.O.S, Tilex, Kingsford, Fresh Step, Glad, Hidden Valley, KC Masterpiece, Brita, and Burt's Bees. Just less than 85% of Clorox's sales stem from its home turf.
<h3>Financial Insights: Clorox</h3>
Negative Revenue Trend: Examining Clorox's financials over 3 months reveals challenges. As of 30 June, 2024, the company experienced a decline of approximately -5.75% in revenue growth, reflecting a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Consumer Staples sector.
Interpreting Earnings Metrics:
<ul>
<li>
Gross Margin: The company sets a benchmark with a high gross margin of 46.45%, reflecting superior cost management and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Clorox's EPS is a standout, portraying a positive bottom-line trend that exceeds the industry average with a current EPS of 1.74.
</li>
</ul>
Debt Management: Clorox's debt-to-equity ratio is below the industry average at 8.85, reflecting a lower dependency on debt financing and a more conservative financial approach.
Insights into Valuation Metrics:
<ul>
<li>
Price to Earnings (P/E) Ratio: Clorox's current Price to Earnings (P/E) ratio of 71.02 is higher than the industry average, indicating that the stock may be overvalued according to market sentiment.
</li>
<li>
Price to Sales (P/S) Ratio: The current P/S ratio of 2.81 is above industry norms, reflecting an elevated valuation for Clorox's stock and potential overvaluation based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Clorox's EV/EBITDA ratio of 31.07 exceeds industry averages, indicating a premium valuation in the market
</li>
</ul>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Insider Activity Matters in Finance</h3>
Insider transactions shouldn't be used primarily to make an investing decision, however, they can be an important factor for an investor to consider.
Considering the legal perspective, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, according to Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.
Nevertheless, insider sells may not necessarily indicate a bearish view and can be influenced by various factors.
<h3>Essential Transaction Codes Unveiled</h3>
When dissecting transactions, the focal point for <a href="https://www.benzinga.com/money/investing-tools">investors</a> is often those occurring in the open market, meticulously detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C indicates the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000021076">Check Out The Full List Of Clorox's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Chief Executive Officer Of Clorox Purchased $5.27M In Stock

Clorox Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) is scheduled to report its quarterly earnings in early November.
The stock's risk/reward is negative heading into the third-quarter results, according to Goldman Sachs <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58aed4dcb85e9300013bf4da/bonnie-herzog">analyst Bonnie Herzog</a>.
The Clorox Thesis: Herzog reiterated a Sell rating for and price target of $132. 
The company faces easy year-ago comps and made progress in restoring product availability and market share. As a result, expectations have risen, Herzog said in the note.
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
Certain areas remain challenging "due to lack of product availability, heightened competition, purchase cycles and category dynamics." That could require more promotional support.
Recent checks suggest that Clorox's promotions are "well above" the pre-Covid levels in certain categories and the company's two-year trends suggest "a sequential moderation in total sales growth," the analyst stated. "As such, we see an environment of elevated promotions and rising concerns around the health of the consumer to limit the rate of retail inventory pipeline fill, esp. in CLX's Household segment, with some sales likely getting pushed out to FQ2," he further wrote.
There is downside to the current consensus estimates and Clorox's organic sales growth in fiscal 2025 is likely to be back-end loaded, Herzog said.
Price Action: Shares of Clorox had declined by 1.03% to $158.94 at the time of publication on Tuesday.
The company received an upgrade from a <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41127080/clorox-positioned-for-comeback-analyst-predicts-earnings-beats-and-3-year-growth-su">Jefferies analyst who predicted an earnings beat</a>. 
Read More:
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40735799/nvidia-beaten-by-clorox-mother-of-all-reports-ahead">Nvidia Beaten By Clorox, Mother Of All Reports Ahead</a></li>
</ul>
Image: Shutterstock

Short Ideas

Reiteration

Movers

This Clorox Analyst Believes There Is Downside To Estimates

Jefferies analyst Kaumil&nbsp;Gajrawala upgraded Clorox Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) to Buy from Hold, raising the price forecast to $187 from $174.
The analyst projects that Clorox will return to its former status as a company delivering peer-leading economic profit growth and returns on capital.
Historically, this performance has warranted a valuation premium of 30% compared to its peers.
According to the analyst, topline growth is already showing signs of improvement, and operating leverage is becoming increasingly attainable.
Clorox has lagged behind its peers in growth reinvestments due to challenges such as COVID, supply chain issues, inflation, and cybersecurity from 2020 to 2024.
Also Read:&nbsp;<a target="_blank" href="https://www.benzinga.com/markets/equities/24/10/41114350/chinese-ev-trio-nio-xpeng-li-auto-surge-higher-in-tuesdays-premarket-whats-going-on" rel="noreferrer noopener">Chinese EV Trio Nio, XPeng, Li Auto Surge Higher In Tuesday's Premarket: What's Going On</a>
However, the analyst notes that this is beginning to change. With ERP deployments primarily expensed and a U.S. rollout expected by fiscal fourth quarter, the company aims to streamline its innovation pipeline, enhance RGM capabilities, and drive SG&amp;A leverage. The analyst forecasts that these changes will lead to earnings beats.
The analyst projects Clorox to achieve a three-year organic sales compound annual growth rate (CAGR) of +3.6% through fiscal 2028. According to the analyst, the company is well-positioned to meet its target of +3-5%, driven by anticipated organic sales growth of +3% in the U.S. and +5.5% internationally, with U.S. sales expected to return to fiscal 2023 levels by fiscal 2025.
Early indicators are promising, as trade spend increases have shown positive results, the analyst adds.
Price Action: CLX shares are trading higher by 0.96% to $164.47 at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/09/41082193/teslas-chinese-rival-nio-snags-1-9b-investment-from-parent-strategic-investors-as-it-forays-into" target="_blank" rel="noreferrer noopener">Tesla's Chinese Rival Nio Snags $1.9B Investment From Parent, Strategic Investors As It Forays Into Mass Market</a></li>
</ul>

General

Clorox Positioned For Comeback: Analyst Predicts Earnings Beats And 3-Year Growth Surge, Upgrades Stock

13 analysts have shared their evaluations of Clorox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">8</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $148.15, a high estimate of $187.00, and a low estimate of $122.00. Experiencing a 0.68% decline, the current average is now lower than the previous average price target of $149.17. 
<img src="https://www.benzinga.com/files/images/story/2024/1727794874_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The standing of Clorox among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kaumil Gajrawala</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$187.00</td>
<td>$174.00</td>
</tr>
<tr>
<td>Wendy Nicholson</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$170.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Linda Bolton Weiser</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$153.00</td>
<td>$153.00</td>
</tr>
<tr>
<td>Wendy Nicholson</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$165.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Lauren Lieberman</td>
<td>Barclays</td>
<td>Raises</td>
<td>Underweight</td>
<td>$130.00</td>
<td>$122.00</td>
</tr>
<tr>
<td>Linda Bolton Weiser</td>
<td>DA Davidson</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$153.00</td>
<td>$162.00</td>
</tr>
<tr>
<td>Andrea Teixeira</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$148.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Stephen Powers</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Hold</td>
<td>$151.00</td>
<td>$144.00</td>
</tr>
<tr>
<td>Robert Moskow</td>
<td>TD Cowen</td>
<td>Announces</td>
<td>Sell</td>
<td>$122.00</td>
<td>-</td>
</tr>
<tr>
<td>Andrea Teixeira</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$150.00</td>
<td>$158.00</td>
</tr>
<tr>
<td>Lauren Lieberman</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$122.00</td>
<td>$132.00</td>
</tr>
<tr>
<td>Wendy Nicholson</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$145.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Chris Carey</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$130.00</td>
<td>$135.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Clorox. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Clorox compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Clorox's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
To gain a panoramic view of Clorox's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/CLX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Clorox analyst ratings.</a>
<h2>Unveiling the Story Behind Clorox</h2>
Since its inception more than 100 years ago, Clorox has grown to play in a variety of categories across the consumer products space, including cleaning supplies, laundry care, trash bags, cat litter, charcoal, food dressings, water-filtration products, and natural personal-care products. Beyond its namesake brand, the firm's portfolio includes Liquid-Plumr, Pine-Sol, S.O.S, Tilex, Kingsford, Fresh Step, Glad, Hidden Valley, KC Masterpiece, Brita, and Burt's Bees. Just less than 85% of Clorox's sales stem from its home turf.
<h3>Clorox's Financial Performance</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Negative Revenue Trend: Examining Clorox's financials over 3 months reveals challenges. As of 30 June, 2024, the company experienced a decline of approximately -5.75% in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Consumer Staples sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Clorox's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 11.35% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Clorox's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 103.1% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Clorox's ROA excels beyond industry benchmarks, reaching 3.74%. This signifies efficient management of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 8.85, Clorox adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Expert Ratings For Clorox

Jefferies analyst Kaumil Gajrawala upgrades Clorox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) from Hold to Buy and raises the price target from $174 to $187.

Jefferies Upgrades Clorox to Buy, Raises Price Target to $187

Citigroup analyst Wendy Nicholson maintains Clorox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) with a Neutral and raises the price target from $165 to $170.

Citigroup Maintains Neutral on Clorox, Raises Price Target to $170

DA Davidson analyst Linda Bolton Weiser maintains Clorox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) with a Neutral and maintains $153 price target.

DA Davidson Maintains Neutral on Clorox, Maintains $153 Price Target

In an interview on CNBC's Mad Money, Linda Rendle said Clorox (CLX) has returned to pre-cyber attack market share levels with most products. The pa...

Clorox CEO: We entered the fiscal year with strong momentum

Barclays raised the firm's price target on Clorox (CLX) to $139 from $137 and keeps an Underweight rating on the shares. The firm says the earnings...

Clorox price target raised to $139 from $137 at Barclays

In a report released today, Linda Bolton Weiser from D.A. Davidson assigned a Hold rating on Clorox (CLX – Research Report), with a price target of...

Clorox's Earnings Beat and Market Recovery Balanced by Cautious Sales Outlook and Divestiture Concerns

DA Davidson analyst Linda Bolton Weiser raised the firm's price target on Clorox (CLX) to $171 from $153 and keeps a Neutral rating on the shares a...

Clorox price target raised to $171 from $153 at DA Davidson

RBC Capital analyst Nik Modi maintained a Hold rating on Clorox (CLX – Research Report) on October 31 and set a price target of $150.00. The compan...

Clorox (CLX) Gets a Hold from RBC Capital

Dividend Champion, Contender, And Challenger Highlights: Week Of November 3

Clorox (CLX – Research Report), the Consumer Defensive sector company, was revisited by a Wall Street analyst today. Analyst Robert Moskow from TD ...

Clorox's Cautious Optimism: Hold Rating Amid Conservative Guidance and Strong Performance

TD Cowen upgraded Clorox (CLX) to Hold from Sell with a price target of $170, up from $155. The company's fiscal 2025 guidance now appears conserva...

Clorox upgraded to Hold from Sell at TD Cowen

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need...

Five Below downgraded, Snowflake upgraded: Wall Street's top analyst calls

ABBV

AMCR

AMZN

APOG

ARDT

CBAN

CGNX

CHCT

CIVB

CRAI

CSWI

CWEN

EBTC

EFSI

FBIZ

FBMS

FCBC

FELE

FIVE

FSBW

GABC

HBCP

HESM

HFWA

IBCP

JBHT

LKFN

MAIN

MASI

MATX

MPLX

NIDB

NXRT

ORRF

OSCR

PACS

PAYX

PODD

RMBS

SBFG

SIRI

SRCE

STBA

TNDM

TXNM

UMBF

WDFN

WTFC

ZION

Press Releases

Clorox Reports Q4 and FY24 Results, Provides FY25 Outlook

CloroxPro Introduces New, Plant-Based Clorox EcoClean Disinfecting Wipes

Clorox to Present at Barclays Global Consumer Staples Conference

Clorox Completes Previously Announced Divestiture of its Better Health VMS Business

Dividends

Clorox Declares Regular Quarterly Dividend of $1.22 Per Share

EPA Names Clorox as 2024 Safer Choice Partner of the Year for Advancing Ingredient and Product Safety

Comments

Clorox

Clorox (CLX) オプション

Clorox (NYSE:CLX) 株価情報, オプションチェーン

ニュース

パートナーシップ

ベンジンガ・グローバル